Evaluation of the Immune Response Induced by CoronaVac 28-Day Schedule Vaccination in a Healthy Population Group
Alejandro Escobar, Felipe E Reyes-López, Mónica L Acevedo, Luis Alonso-Palomares, Fernando Valiente-Echeverría, Ricardo Soto-Rifo, Hugo Portillo, Jimena Gatica, Ivan Flores, Estefanía Nova-Lamperti, Carlos Barrera-Avalos, María Rosa Bono, Leonardo Vargas, Valeska Simon, Elias Leiva-Salcedo, Cecilia Vial, Juan Hormazabal, Lina Jimena Cortes, Daniel Valdés, Ana M Sandino, Mónica Imarai, Claudio Acuña-Castillo, Alejandro Escobar, Felipe E Reyes-López, Mónica L Acevedo, Luis Alonso-Palomares, Fernando Valiente-Echeverría, Ricardo Soto-Rifo, Hugo Portillo, Jimena Gatica, Ivan Flores, Estefanía Nova-Lamperti, Carlos Barrera-Avalos, María Rosa Bono, Leonardo Vargas, Valeska Simon, Elias Leiva-Salcedo, Cecilia Vial, Juan Hormazabal, Lina Jimena Cortes, Daniel Valdés, Ana M Sandino, Mónica Imarai, Claudio Acuña-Castillo
Abstract
CoronaVac vaccine from Sinovac Life Science is currently being used in several countries. In Chile, the effectiveness of preventing hospitalization is higher than 80% with a vaccination schedule. However, to date, there are no data about immune response induction or specific memory. For this reason, we recruited 15 volunteers without previous suspected/diagnosed COVID-19 and with negative PCR over time to evaluate the immune response to CoronaVac 28 and 90 days after the second immunization (dpi). The CoronaVac administration induces total and neutralizing anti-spike antibodies in all vaccinated volunteers at 28 and 90 dpi. Furthermore, using ELISpot analysis to assay cellular immune responses against SARS-CoV-2 spike protein, we found an increase in IFN-gamma- and Granzyme B-producing cells in vaccinated volunteers at 28 and 90 dpi. Together, our results indicate that CoronaVac induces a robust humoral immune response and cellular immune memory of at least 90 dpi.
Keywords: COVID-19; CoronaVac; SARS-CoV-2; herd immunity; immunological memory; neutralizing antibodies; vaccine.
Conflict of interest statement
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Copyright © 2022 Escobar, Reyes-López, Acevedo, Alonso-Palomares, Valiente-Echeverría, Soto-Rifo, Portillo, Gatica, Flores, Nova-Lamperti, Barrera-Avalos, Bono, Vargas, Simon, Leiva-Salcedo, Vial, Hormazabal, Cortes, Valdés, Sandino, Imarai and Acuña-Castillo.
Figures
References
- Tregoning JS, Flight KE, Higham SL, Wang Z, Pierce BF. Progress of the COVID-19 Vaccine Effort: Viruses, Vaccines and Variants Versus Efficacy, Effectiveness and Escape. Nat Rev Immunol (2021) 21(10):626–36. doi: 10.1038/s41577-021-00592-1
- Mulligan MJ, Lyke KE, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. . Phase I/II Study of COVID-19 RNA Vaccine BNT162b1 in Adults. Nature (2020) 586:589–93. doi: 10.1038/s41586-020-2639-4
- Palacios R, Patiño EG, de Oliveira Piorelli R, Conde MTRP, Batista AP, Zeng G, et al. . Double-Blind, Randomized, Placebo-Controlled Phase III Clinical Trial to Evaluate the Efficacy and Safety of Treating Healthcare Professionals With the Adsorbed COVID-19 (Inactivated) Vaccine Manufactured by Sinovac – PROFISCOV: A Structured Summary of a. Trials (2020) 21:21–3. doi: 10.1186/s13063-020-04775-4
- Bueno SM, Abarca K, González PA, Gálvez NMS, Soto JA, Duarte LF, et al. . Interim Report : Safety and Immunogenicity of an Inactivated Vaccine. medRxiv (2021). doi: 10.1101/2021.03.31.21254494
- Ministerio de Salud Gobierno de Chile . Ficha Vacuna Contra Sars-Cov-2 Vacuna Coronavac Laboratorio Sinovac Life Science® (2021). Available at: (Accessed August 23, 2021).
- Jara A, Undurraga EA, González C, Paredes F, Fontecilla T, Jara G, et al. . Effectiveness of an Inactivated SARS-CoV-2 Vaccine in Chile. N Engl J Med (2021) 385:875–84. doi: 10.1056/nejmoa2107715
- Huang AT, Garcia-Carreras B, Hitchings MDT, Yang B, Katzelnick LC, Rattigan SM, et al. . A Systematic Review of Antibody Mediated Immunity to Coronaviruses: Kinetics, Correlates of Protection, and Association With Severity. Nat Commun (2020) 11:1–16. doi: 10.1038/s41467-020-18450-4
- Beltrán-Pavez C, Riquelme-Barrios S, Oyarzún-Arrau A, Gaete-Argel A, González-Stegmaier R, Cereceda-Solis K, et al. . Insights Into Neutralizing Antibody Responses in Individuals Exposed to SARS-CoV-2 in Chile. Sci Adv (2021) 7(7):eabe6855. doi: 10.1126/sciadv.abe6855
- Palgen JL, Tchitchek N, Elhmouzi-Younes J, Delandre S, Namet I, Rosenbaum P, et al. . Prime and Boost Vaccination Elicit a Distinct Innate Myeloid Cell Immune Response. Sci Rep (2018) 8:1–18. doi: 10.1038/s41598-018-21222-2
- Channappanavar R, Zhao J. Perlman S. T Cell-Mediated Immune Response to Respiratory Coronaviruses. Immunol Res (2014) 59:118–28. doi: 10.1007/s12026-014-8534-z
- Dosch SF, Mahajan SD, Collins AR. SARS Coronavirus Spike Protein-Induced Innate Immune Response Occurs via Activation of the NF-κb Pathway in Human Monocyte Macrophages In Vitro . Virus Res (2009) 142:19–27. doi: 10.1016/j.virusres.2009.01.005
- Li T, Kenney AD, Liu H, Fiches GN, Zhou D, Ayan Biswas J, et al. . SARS-CoV-2 Nsp14 Activates NF-κb Signaling and Induces IL-8 Upregulation. BioRxiv (2021). doi: 10.1101/2021.05.26.445787
- Li J, Rong L, Cui R, Feng J, Jin Y, Yu Y, et al. . Dynamic Changes in Serum IL-6, IL-8, and IL-10 Are Associated With the Outcome of Patients With Severe COVID-19 in ICU. Res Sq (2021) 10(4):3706–14. doi: 10.21203/-83336/v1
- Amanna IJ, Carlson NE, Slifka MK. Duration of Humoral Immunity to Common Viral and Vaccine Antigens. N Engl J Med (2007) 357:1903–15. doi: 10.1542/peds.2008-2139LLLL
- Khoury DS, Cromer D, Reynaldi A, Schlub TE, Wheatley AK, Juno JA, et al. . Neutralizing Antibody Levels Are Highly Predictive of Immune Protection From Symptomatic SARS-CoV-2 Infection. Nat Med (2021) 27:1205–11. doi: 10.1038/s41591-021-01377-8
- Vabret N, Britton GJ, Gruber C, Hegde S, Kim J, Kuksin M, et al. . Immunology of COVID-19: Current State of the Science. Immunity (2020) 52:910–41. doi: 10.1016/j.immuni.2020.05.002
- Sahin U, Muik A, Derhovanessian E, Vogler I, Kranz LM, Vormehr M, et al. . COVID-19 Vaccine BNT162b1 Elicits Human Antibody and TH1 T Cell Responses. Nature (2020) 586:594–9. doi: 10.1038/s41586-020-2814-7
- Yang G, Feng F, Li X, Zhang T, Li X, Li B. Changes of Lymphocyte Subsets in Patients With COVID-19 and Clinical Significance: A Case-Control Observational Study. J Bio-X Res (2021) 4:36–9. doi: 10.1097/jbr.0000000000000089
Source: PubMed